Literature DB >> 22492958

Glioblastoma blood flow measured with stable xenon CT indicates tumor necrosis, vascularity, and brain invasion.

Matthew Crocker1, Samira Saadoun, Alexa Jury, Chris Jones, Stergios Zacharoulis, Samiwel Thomas, Reyer Zwiggelaar, Leslie R Bridges, B Anthony Bell, Marios C Papadopoulos.   

Abstract

Tumor vasculature is a promising therapeutic target in glioblastoma. Imaging tumor blood flow may help assess the efficacy of anti-angiogenic treatments. We determined the clinical usefulness of stable xenon CT performed preoperatively in patients with glioblastoma. This is a prospective cohort study. We determined absolute tumor blood flow before surgery in 38 patients with glioblastoma using stable xenon CT. We also histologically examined tumor specimens obtained from surgery and quantified their vascularity (by CD31 and CD105 immunostain), necrosis (by hematoxylin and eosin stain), and the presence of neuronal processes (by neurofilament immunostain). According to the xenon CT blood flow map, there are 3 types of glioblastoma. Type I glioblastomas have unimodal high blood flow histograms; histologically there is little necrosis and vascular proliferation. Type II glioblastomas have unimodal low blood flow histograms; histologically there is prominent necrosis and vascular proliferation. We propose that in type II glioblastoma, the abnormal vessels induced by hypoxia are inefficient at promoting blood flow. Type III glioblastomas have multimodal blood flow histograms. Histologically there is significant neuronal tissue within the tumor. Patients with type III glioblastomas were more likely to develop a post-surgical deficit, consistent with the inclusion of normal tissue within the tumor. Preoperative measurement of absolute blood flow with stable xenon CT in patients with glioblastoma predicts key biological features of the tumor and may aid surgical planning.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22492958      PMCID: PMC3337310          DOI: 10.1093/neuonc/nos063

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  36 in total

Review 1.  Technological advances in MRI measurement of brain perfusion.

Authors:  Jeff H Duyn; Peter van Gelderen; Lalith Talagala; Alan Koretsky; Jacco A de Zwart
Journal:  J Magn Reson Imaging       Date:  2005-12       Impact factor: 4.813

2.  Threshold of regional cerebral blood flow for infarction in patients with acute cerebral ischemia.

Authors:  M Ohashi; A Tsuji; M Kaneko; M Matsuda
Journal:  J Neuroradiol       Date:  2005-12       Impact factor: 3.447

3.  Molecular imaging (PET) of brain tumors.

Authors:  Sandip Basu; Abass Alavi
Journal:  Neuroimaging Clin N Am       Date:  2009-11       Impact factor: 2.264

4.  Magnetic resonance perfusion and permeability imaging in brain tumors.

Authors:  Saulo Lacerda; Meng Law
Journal:  Neuroimaging Clin N Am       Date:  2009-11       Impact factor: 2.264

Review 5.  Hypoxia helps glioma to fight therapy.

Authors:  Verena Amberger-Murphy
Journal:  Curr Cancer Drug Targets       Date:  2009-05       Impact factor: 3.428

6.  Cerebral blood flow thresholds predicting new hypoattenuation areas due to macrovascular ischemia during the acute phase of severe and complicated aneurysmal subarachnoid hemorrhage. A preliminary study.

Authors:  A Chieregato; A Tanfani; A Noto; S Fronza; F Cocciolo; E Fainardi
Journal:  Acta Neurochir Suppl       Date:  2008

Review 7.  New molecular targets in angiogenic vessels of glioblastoma tumours.

Authors:  Joshua C Anderson; Braden C McFarland; Candece L Gladson
Journal:  Expert Rev Mol Med       Date:  2008-08-07       Impact factor: 5.600

Review 8.  Angiogenesis as a therapeutic target in malignant gliomas.

Authors:  Andrew S Chi; A Gregory Sorensen; Rakesh K Jain; Tracy T Batchelor
Journal:  Oncologist       Date:  2009-06-01

Review 9.  Invasion as limitation to anti-angiogenic glioma therapy.

Authors:  K Lamszus; P Kunkel; M Westphal
Journal:  Acta Neurochir Suppl       Date:  2003

10.  Haemodynamic evaluation of cerebral gliomas using XeCT.

Authors:  T Nakagawa; R Tanaka; S Takeuchi; N Takeda
Journal:  Acta Neurochir (Wien)       Date:  1998       Impact factor: 2.216

View more
  1 in total

1.  Liquid biopsies for early diagnosis of brain tumours: in silico mathematical biomarker modelling.

Authors:  Johanna A Blee; Xia Liu; Abigail J Harland; Kavi Fatania; Stuart Currie; Kathreena M Kurian; Sabine Hauert
Journal:  J R Soc Interface       Date:  2022-08-03       Impact factor: 4.293

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.